Literature DB >> 18592154

Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation.

Masatoshi Ishigami1, Takashi Honda, Akihiko Okumura, Tetsuya Ishikawa, Makoto Kobayashi, Yoshiaki Katano, Yasuhiro Fujimoto, Tetsuya Kiuchi, Hidemi Goto.   

Abstract

BACKGROUND: Consideration of the prognosis of patients with liver cirrhosis is important when determining the appropriate timing of liver transplantation. Especially in Japan, where 99% of liver transplants are from living donors, timing is very important not only for the patient but also for the family, who need time to consider the various factors involved in living donations.
METHODS: To clarify the applicability of the Model for End-Stage Liver Disease (MELD) score in Japanese patients with cirrhosis, changes in the MELD score over 24 months were reviewed in 79 patients with cirrhosis who subsequently died of liver failure (n=33) or who survived 24 months (n=46). All patients had Child class B or C cirrhosis at the start of follow-up. We also compared their survival with that of 30 patients treated by living donor liver transplantation (LDLT) in our institute to determine the proper timing of transplantation in patients with cirrhosis.
RESULTS: Significant stratification of survival curves was observed for MELD scores of <12, 12-15, 15-18, and >18 (P=0.0018). A significant survival benefit of LDLT was observed in patients with MELD score >or=15 (P=0.0181), and significantly more risk with transplantation was observed in those with MELD score <15 compared with that of patients in whom the disease followed its natural course (P=0.0168).
CONCLUSIONS: MELD score is useful for predicting 1-year survival in Japanese patients with cirrhosis. MELD scores of 15 had discriminatory value for indicating a survival benefit to be gained by liver transplantation and thus can be used to help patients and their families by identifying patients who would benefit from LDLT.

Entities:  

Mesh:

Year:  2008        PMID: 18592154     DOI: 10.1007/s00535-008-2168-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  56 in total

Review 1.  Living-donor liver transplantation: 12 years of experience in Asia.

Authors:  Chao-Long Chen; Sheung-Tat Fan; Sung-Gyu Lee; Masatoshi Makuuchi; Koichi Tanaka
Journal:  Transplantation       Date:  2003-02-15       Impact factor: 4.939

2.  Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

Authors:  M Novella; R Solà; G Soriano; M Andreu; J Gana; J Ortiz; S Coll; M Sàbat; M C Vila; C Guarner; F Vilardell
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.

Authors:  Bimaljit S Sandhu; Rajesh Gupta; Jayant Sharma; Jagdeep Singh; Nandagudi S Murthy; Shiv K Sarin
Journal:  J Gastroenterol Hepatol       Date:  2005-04       Impact factor: 4.029

4.  Screening for hepatocellular carcinoma in patients with advanced cirrhosis.

Authors:  N Chalasani; J C Horlander; A Said; H Hoen; K K Kopecky; S M Stockberger; R Manam; P Y Kwo; L Lumeng
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

5.  A survey of liver transplantation from living adult donors in the United States.

Authors:  Robert S Brown; Mark W Russo; Michelle Lai; Mitchell L Shiffman; Michael C Richardson; James E Everhart; Jay H Hoofnagle
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

6.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

7.  Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez De La Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2002-07-10       Impact factor: 2.953

Review 8.  Living-donor liver transplantation--European experiences.

Authors:  Utz Settmacher; Tom Theruvath; Andreas Pascher; Peter Neuhaus
Journal:  Nephrol Dial Transplant       Date:  2004-07       Impact factor: 5.992

9.  A prospective study of bacterial infections in patients with cirrhosis.

Authors:  W R Caly; E Strauss
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

10.  Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.

Authors:  René Adam; Paul McMaster; John G O'Grady; Denis Castaing; Jurgen L Klempnauer; Neville Jamieson; Peter Neuhaus; Jan Lerut; Mauro Salizzoni; Stephen Pollard; Ferdinand Muhlbacher; Xavier Rogiers; Juan Carlos Garcia Valdecasas; Joaquin Berenguer; Daniel Jaeck; Enrique Moreno Gonzalez
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

View more
  4 in total

1.  A Novel prognostic scoring system to predict 3-month mortality risk in patients with acute-on-chronic liver failure in hepatitis B: a retrospective cohort study.

Authors:  Yu-Bao Zheng; Shi-Bin Xie; Dong-Ying Xie; Liang Peng; Zi-Ying Lei; Hong Deng; Bin-Liang Lin; Chao-Shuang Lin; Zhi-Xin Zhao; Wei-Min Ke; Zhi-Liang Gao
Journal:  Hepatol Int       Date:  2012-01-29       Impact factor: 6.047

2.  Impact of preoperative uncontrollable hepatic hydrothorax and massive ascites in adult liver transplantation.

Authors:  Kosuke Endo; Taku Iida; Shintaro Yagi; Atsushi Yoshizawa; Yasuhiro Fujimoto; Kohei Ogawa; Yasuhiro Ogura; Akira Mori; Toshimi Kaido; Shinji Uemoto
Journal:  Surg Today       Date:  2014-02-08       Impact factor: 2.549

Review 3.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

4.  Dynamic changes of clinical features that predict the prognosis of acute-on-chronic hepatitis B liver failure: a retrospective cohort study.

Authors:  Yu-Bao Zheng; Zhan Lian Huang; Zhe Bin Wu; Min Zhang; Yu Rong Gu; Yu Jie Su; Chao Shuang Lin; Rui Hua Zhu; Bin Liang Lin; Zhi Liang Gao
Journal:  Int J Med Sci       Date:  2013-09-23       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.